Abstract: Methods and kits for monitoring or providing a prognosis for a subject having uveal melanoma are described. The methods include obtaining a biological sample from the subject, determining the expression level of one or more uveal melanoma-associated miRs and/or miR biogenesis factors in the biological sample, and characterizing the subject as high risk if one or more uveal melanoma-associated miRs and/or miR biogenesis factors are differentially expressed as compared with a corresponding control.